Cascadian Therapeutics Inc (USA) news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

CASC 1.67 +0.08 (5.35%)
price chart
Company Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces ...
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC), a clinical-stage biopharmaceutical company, announced that the United States Adopted Names (USAN) Council and the International Nonproprietary Names (INN) Expert Group have approved the ...
Pay Close Attention To These Analyst Ratings Actinium Pharmaceuticals Inc ...
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) currently has mean rating of 3.00 while 2 analysts have recommended the shares as 'BUY', 1 commented as 'OUTPERFORM' and 1 commented as 'HOLD'.
Stock Higher in Current Session Trade: Cascadian Therapeutics, Inc. (NASDAQ ...  Engelwood Daily
Under the Microscope: Zeroing in on Shares of Cascadian Therapeutics, Inc ...  Duncan Research
Stock Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Receives ONT-380 ...
Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the ONT-380 program in advanced HER2+ metastatic breast cancer has received Fast Track designation from the U.S. Food and Drug ...
Cascadian boosted by FDA fast track for cancer drug  Proactive Investors USA & Canada
Cascadian's lead product candidate Fast Track'd for subtype of ...  Seeking Alpha
Company Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces ...
casc Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
Oncothyreon (ONTY) Changes Name to Cascadian Therapeutics; Will Begin Trading ...
Oncothyreon Inc. (Nasdaq: ONTY) (Nasdaq: CASC) announced that the Company is changing its name to Cascadian Therapeutics, Inc. and will trade on the NASDAQ Global Select Market under the new ticker symbol “CASC,” effective at market open on ...
Oncothyreon Renames Itself Cascadian Therapeutics (NASDAQ:ONTY)  Sonoran Weekly Review
Oncothyreon Presents Phase 1b Results of ONT-380 in Combination with T-DM1 ...  GlobeNewswire (press release)
Cascadian Therapeutics, Inc. (NASDAQ:CASC) Insider Activities Are in the Air
Cascadian Therapeutics, Inc. (NASDAQ:CASC) up 23.42% for the past 5 days, is under coverage of 4 analysts who collectively assign a hold rating on stock.
Biotech Stock Mailbag: Cascadian Therapeutics, Global Blood Therapeutics, Bad ...
In this edition of the Biotech Stock Mailbag, I discuss the future of Cascadian Therapeutics (CASC) and its breast cancer drug ONT-380.
Current Cascadian Therapeutics, Inc. (NASDAQ:CASC) PT Means Stock Is Worth ...
Cascadian Therapeutics, Inc. (NASDAQ:CASC) up 28.42 per cent in the past week, is under coverage of 5 analysts who collectively recommend a hold rating on stock.
Biotech Beat: Analysts Weigh In On EXACT Sciences Corporation (EXAS ...
Exact shares rallied yesterday on an apparent leaked JAMA article unveiling that USPSTF highly recommends colon cancer screening from age 50 to 75, but will no longer rank tests; instead, it is providing a list of acceptable ones that includes FITDNA ...
Latest Cascadian Therapeutics, Inc. (NASDAQ:CASC) Target Price Suggests Stock ...
Cascadian Therapeutics, Inc. (NASDAQ:CASC) up 10.53 per cent in the past week, is under coverage of 5 analysts who collectively recommend a hold rating on stock.
Stock Performance to Track: Cascadian Therapeutics, Inc. (NASDAQ:CASC)  News Oracle